Dynavax Escapes Shareholder Suit Over Hepatitis Vaccine
A California federal court on Tuesday tossed a proposed class action alleging biopharmaceutical company Dynavax Technologies Corp. misrepresented the safety of its Heplisav vaccine for hepatitis B, eventually causing share prices...To view the full article, register now.
Already a subscriber? Click here to view full article